BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Berenguer J, Zamora FX, Aldámiz-echevarría T, Von Wichmann MA, Crespo M, López-aldeguer J, Carrero A, Montes M, Quereda C, Téllez MJ, Galindo MJ, Sanz J, Santos I, Guardiola JM, Barros C, Ortega E, Pulido F, Rubio R, Mallolas J, Tural C, Jusdado JJ, Pérez G, Díez C, Álvarez-pellicer J, Esteban H, Bellón JM, González-garcía J, Miralles P, Cosín J, López J, Padilla B, Parras F, Carrero A, Aldamiz-echevarría T, Tejerina F, Gutiérrez I, Ramírez M, Carretero S, Bellón J, Berenguer J, Alvarez-pellicer J, Rodríguez E, Arribas J, Montes M, Bernardino I, Pascual J, Zamora F, Peña J, Arnalich F, Díaz M, González-garcía J, Bustinduy M, Iribarren J, Rodríguez-arrondo F, Von-wichmann M, Blanes M, Cuellar S, Lacruz J, Montero M, Salavert M, López-aldeguer J, Callau P, Miró J, Gatell J, Mallolas J, Ferrer A, Galindo M, Van den Eynde E, Pérez M, Ribera E, Crespo M, Vergas J, Téllez M, Casado J, Dronda F, Moreno A, Pérez-elías M, Sanfrutos M, Moreno S, Quereda C, Jou A, Tural C, Arranz A, Casas E, de Miguel J, Schroeder S, Sanz J, Condés E, Barros C, Sanz J, Santos I, Hernando A, Rodríguez V, Rubio R, Pulido F, Domingo P, Guardiola J, Ortiz L, Ortega E, Torres R, Cervero M, Jusdado J, Rodríguez-zapata M, Pérez G, Gaspar G, Barquilla E, Ramírez M, Moyano B, Aznar E, Esteban H; for the Grupo de Estudio del SIDA (GESIDA) HIV/HCV Cohort Study Group. Comparison of the Prognostic Value of Liver Biopsy and FIB-4 Index in Patients Coinfected With HIV and Hepatitis C Virus. Clinical Infectious Diseases 2015;60:950-8. [DOI: 10.1093/cid/ciu939] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Jiménez-Sousa MA, Berenguer J, García-Álvarez M, Gutierrez-Rivas M, Aldámiz-Echevarria T, Tejerina F, Diez C, Vázquez-Morón S, Resino S. Impact of patatin-like phospholipase domain-containing 3 gene polymorphism (rs738409) on severity of liver disease in HIV/hepatitis C virus-coinfected patients. AIDS 2016;30:465-70. [PMID: 26760234 DOI: 10.1097/QAD.0000000000000908] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
2 Mussini C, Lorenzini P, Puoti M, Lichtner M, Lapadula G, Di Giambenedetto S, Antinori A, Madeddu G, Cozzi-Lepri A, d'Arminio Monforte A, De Luca A; ICONA Foundation Study Group. Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus. PLoS One 2015;10:e0140877. [PMID: 26640953 DOI: 10.1371/journal.pone.0140877] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
3 Li DK, Ren Y, Fierer DS, Rutledge S, Shaikh OS, Lo Re V 3rd, Simon T, Abou-Samra AB, Chung RT, Butt AA. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study. Hepatology 2018;67:2244-53. [PMID: 29205416 DOI: 10.1002/hep.29707] [Cited by in Crossref: 99] [Cited by in F6Publishing: 100] [Article Influence: 24.8] [Reference Citation Analysis]
4 Berenguer J, Rodríguez-Castellano E, Carrero A, Von Wichmann MA, Montero M, Galindo MJ, Mallolas J, Crespo M, Téllez MJ, Quereda C, Sanz J, Barros C, Tural C, Santos I, Pulido F, Guardiola JM, Rubio R, Ortega E, Montes ML, Jusdado JJ, Gaspar G, Esteban H, Bellón JM, González-García J; GESIDA HIV/HCV Cohort Study Group. Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology 2017;66:344-56. [PMID: 28109003 DOI: 10.1002/hep.29071] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 7.2] [Reference Citation Analysis]
5 Rasmussen DN, Thiele M, Johansen S, Kjærgaard M, Lindvig KP, Israelsen M, Antonsen S, Detlefsen S, Krag A; GALAXY., MicrobLiver consortia. Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease. J Hepatol 2021:S0168-8278(21)00411-6. [PMID: 34118335 DOI: 10.1016/j.jhep.2021.05.037] [Reference Citation Analysis]
6 He J, Liu X, Duan S, Ye R, Yang Y, Wang J, He N. Untargeted Plasma Metabolomics Reveals Extensive Metabolic Alterations Among Treatment-Naive Human Immunodeficiency Virus/Hepatitis C Virus Co-Infected Patients with Liver Disease Progression. AIDS Res Hum Retroviruses 2022;38:378-93. [PMID: 35383478 DOI: 10.1089/AID.2021.0123] [Reference Citation Analysis]
7 Berenguer M, García-Eliz M, Baiguera C, Puoti M. Beyond cure: preventing and managing the complications of end-stage liver disease. Curr Opin HIV AIDS 2015;10:355-60. [PMID: 26248123 DOI: 10.1097/COH.0000000000000184] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, Song K, Han KH. Transient Elastography is Superior to FIB-4 in Assessing the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. Medicine (Baltimore) 2016;95:e3434. [PMID: 27196449 DOI: 10.1097/MD.0000000000003434] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
9 Kooij KW, Wit FW, van Zoest RA, Schouten J, Kootstra NA, van Vugt M, Prins M, Reiss P, van der Valk M; AGEhIV Cohort Study Group. Liver fibrosis in HIV-infected individuals on long-term antiretroviral therapy: associated with immune activation, immunodeficiency and prior use of didanosine. AIDS 2016;30:1771-80. [PMID: 27088320 DOI: 10.1097/QAD.0000000000001119] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
10 Ding Y, Duan S, Ye R, Yang Y, Yao S, Wang J, Cao D, Liu X, Lu L, Jia M, Wu Z, He N. More improvement than progression of liver fibrosis following antiretroviral therapy in a longitudinal cohort of HIV-infected patients with or without HBV and HCV co-infections. J Viral Hepat 2017;24:412-20. [PMID: 27925409 DOI: 10.1111/jvh.12658] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
11 Naggie S, Lusk S, Thompson JW, Mock M, Moylan C, Lucas JE, Dubois L, St John-Williams L, Moseley MA, Patel K. Metabolomic Signature as a Predictor of Liver Disease Events in Patients With HIV/HCV Coinfection. J Infect Dis 2020;222:2012-20. [PMID: 32502252 DOI: 10.1093/infdis/jiaa316] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Ramos JM, González-Alcaide G, Gutiérrez F. [Bibliometric analysis of the Spanish scientific production in Infectious Diseases and Microbiology]. Enferm Infecc Microbiol Clin 2016;34:166-76. [PMID: 26049175 DOI: 10.1016/j.eimc.2015.04.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
13 Pérez-Latorre L, Sánchez-Conde M, Miralles P, López JC, Parras F, Tejerina F, Aldámiz-Echevarría T, Carrero A, Díez C, Ramírez M, Gutiérrez I, Bellón JM, Bañares R, Berenguer J. Prognostic value of liver stiffness in HIV/HCV-Coinfected patients with decompensated cirrhosis. BMC Infect Dis 2018;18:170. [PMID: 29642845 DOI: 10.1186/s12879-018-3067-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Sherman KE, Rockstroh J, Thomas D. Human immunodeficiency virus and liver disease: An update. Hepatology 2015;62:1871-82. [PMID: 26340591 DOI: 10.1002/hep.28150] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
15 Irvine KM, Wockner LF, Shanker M, Fagan KJ, Horsfall LU, Fletcher LM, Ungerer JP, Pretorius CJ, Miller GC, Clouston AD, Lampe G, Powell EE. The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease. Liver Int 2016;36:370-7. [PMID: 26104018 DOI: 10.1111/liv.12896] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
16 Xiao L, Wang W, Xian J, Zhang W, Li Y, Yang X, Lu L. Annual Change in FIB-4, but not in APRI, was a Strong Predictor for Liver Disease Progression in Chinese Patients with Chronic Hepatitis C. Hepat Mon 2017;18. [DOI: 10.5812/hepatmon.57250] [Reference Citation Analysis]
17 Li DK, Yan P, Abou-Samra AB, Chung RT, Butt AA. Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVES. Aliment Pharmacol Ther 2018;47:246-58. [PMID: 29105111 DOI: 10.1111/apt.14391] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
18 Yongpisarn T, Thimphitthaya C, Laoveeravat P, Wongjarupong N, Chaiteerakij R. Non-invasive tests for predicting liver outcomes in chronic hepatitis C patients: A systematic review and meta-analysis. World J Hepatol 2021; 13(8): 949-968 [PMID: 34552701 DOI: 10.4254/wjh.v13.i8.949] [Reference Citation Analysis]
19 Saleem N, Miller LS, Dadabhai AS, Cartwright EJ. Using vibration controlled transient elastography and FIB-4 to assess liver cirrhosis in a hepatitis C virus infected population. Medicine (Baltimore) 2021;100:e26200. [PMID: 34115003 DOI: 10.1097/MD.0000000000026200] [Reference Citation Analysis]
20 Tsochatzis EA, Castera L. Assessing liver disease in HIV–HCV coinfected patients: . Current Opinion in HIV and AIDS 2015;10:316-22. [DOI: 10.1097/coh.0000000000000176] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
21 Li Y, Xie J, Han Y, Wang H, Lv W, Guo F, Qiu Z, Li Y, Du S, Song X, Zhu T, Thio CL, Li T. Combination Antiretroviral Therapy Is Associated With Reduction in Liver Fibrosis Scores in HIV-1-Infected Subjects. Medicine (Baltimore) 2016;95:e2660. [PMID: 26844493 DOI: 10.1097/MD.0000000000002660] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
22 Ključević Ž, Benzon B, Ključević N, Veršić Bratinčević M, Sutlović D. Liver damage indices as a tool for modifying methadone maintenance treatment: a cross-sectional study. Croat Med J 2018;59:298-306. [PMID: 30610772 [PMID: 30610772 DOI: 10.3325/cmj.2018.59.298] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
23 Kim HN, Crane HM, Rodriguez CV, Van Rompaey S, Mayer KH, Christopoulos K, Napravnik S, Chander G, Hutton H, McCaul ME, Cachay ER, Mugavero MJ, Moore R, Geng E, Eron JJ, Saag MS, Merrill JO, Kitahata MM. The Role of Current and Historical Alcohol Use in Hepatic Fibrosis Among HIV-Infected Individuals. AIDS Behav 2017;21:1878-84. [PMID: 28035496 DOI: 10.1007/s10461-016-1665-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
24 Mandorfer M, Schwabl P, Steiner S, Reiberger T, Peck-Radosavljevic M. Advances in the management of HIV/HCV coinfection. Hepatol Int. 2016;10:424-435. [PMID: 26758592 DOI: 10.1007/s12072-015-9691-4] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
25 Maev IV, Kuznetsova EI, Andreev DN, Dicheva DT. [Diagnostic accuracy of predictive indexes of liver fibrosis in patients with chronic hepatitis C]. Ter Arkh 2020;92:24-8. [PMID: 32598714 DOI: 10.26442/00403660.2020.02.000261] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Kim HN, Nance R, Van Rompaey S, Delaney JC, Crane HM, Cachay ER, Geng E, Boswell SL, Rodriguez B, Eron JJ, Saag M, Moore RD, Kitahata MM. Poorly Controlled HIV Infection: An Independent Risk Factor for Liver Fibrosis. JAIDS Journal of Acquired Immune Deficiency Syndromes 2016;72:437-43. [DOI: 10.1097/qai.0000000000000992] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
27 Aldámiz-Echevarría T, Resino S, Bellón JM, Jiménez-Sousa MA, Miralles P, Medrano LM, Carrero A, Díez C, Pérez-Latorre L, Fanciulli C, Garcia-Broncano P, Berenguer J. European mitochondrial haplogroups predict liver-related outcomes in patients coinfected with HIV and HCV: a retrospective study. J Transl Med 2019;17:244. [PMID: 31349790 DOI: 10.1186/s12967-019-1997-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Chalouni M, Sogni P, Miailhes P, Lacombe K, Poizot-Martin I, Chas J, Vittecoq D, Neau D, Aumaitre H, Alric L, Piroth L, Bouchaud O, Katlama C, Morlat P, Lascoux-Combe C, Gervais A, Naqvi A, Rosenthal E, Garipuy D, Barange K, Esterle L, Salmon D, Wittkop L;  ANRS CO13 HEPAVIH study group. Liver stiffness and fibrosis-4 alone better predict liver events compared with aspartate aminotransferase to platelet ratio index in a cohort of human immunodeficiency virus and hepatitis C virus co-infected patients from ANRS CO13 HEPAVIH cohort. Eur J Gastroenterol Hepatol. 2019;31:1387-1396. [PMID: 31033848 DOI: 10.1097/meg.0000000000001408] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
29 Focà E, Fabbiani M, Prosperi M, Quiros Roldan E, Castelli F, Maggiolo F, Di Filippo E, Di Giambenedetto S, Gagliardini R, Saracino A, Di Pietro M, Gori A, Sighinolfi L, Pan A, Postorino MC, Torti C; Italian MASTER Cohort. Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study. Medicine (Baltimore) 2016;95:e4091. [PMID: 27442636 DOI: 10.1097/MD.0000000000004091] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
30 Campa A, Martinez SS, Sherman KE, Greer JP, Li Y, Garcia S, Stewart T, Ibrahimou B, Williams OD, Baum MK. Cocaine Use and Liver Disease are Associated with All-Cause Mortality in the Miami Adult Studies in HIV (MASH) Cohort. J Drug Abuse 2016;2:27. [PMID: 28540368 DOI: 10.21767/2471-853X.100036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]